# DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

**POLICY:** Inflammatory Conditions – Cimzia Drug Quantity Management Policy – Per Days

Cimzia<sup>®</sup> (certolizumab pegol subcutaneous injection [lyophilized powder or solution]
 UCB)

**REVIEW DATE:** 12/15/2022

#### **OVERVIEW**

Cimzia, a tumor necrosis factor inhibitor (TNFi), is indicated for the following uses:1

- **Ankylosing spondylitis**, for the treatment of adults with active disease.
- Crohn's disease, for reducing signs and symptoms and maintaining clinical responses in adults
  with moderate to severe active disease who have had an inadequate response to conventional
  therapy.
- Non-radiographic axial spondyloarthritis, in patients with objective signs of inflammation.
- **Plaque psoriasis**, for the treatment of adults with moderately to severely active disease who are candidates for systemic therapy or phototherapy.
- **Psoriatic arthritis**, for the treatment of adult patients with active disease.
- **Rheumatoid arthritis**, for the treatment of adults with moderately to severely active disease.

# **Dosing**

Cimzia is administered by subcutaneous (SC) injection.<sup>1</sup> Injection sites should be rotated and injections should not be given into areas where the skin is tender, bruised, red or hard. When a 400 mg dose is needed, it should be given as two 200 mg SC injections at separate sites in the thigh or abdomen.

- **Ankylosing Spondylitis**: 400 mg initially and at Week 2 and Week 4, followed by 200 mg once every 2 weeks (400 mg every 4 weeks may also be considered).
- Crohn's Disease: 400 mg initially and at Week 2 and Week 4. If response occurs, follow with 400 mg once every 4 weeks.
- Non-Radiographic Axial Spondyloarthritis: 400 mg initially and at Week 2 and Week 4, followed by 200 mg once every 2 weeks or 400 mg every 4 weeks.
- **Plaque Psoriasis:** 400 mg once every other week. For some patients (with body weight ≤ 90 kg), may consider 400 mg initially and at Week 2 and Week 4, followed by 200 mg once every other week.
- **Psoriatic Arthritis**: 400 mg initially and at Week 2 and Week 4, followed by 200 mg once every other week. For maintenance dosing, 400 mg every 4 weeks may be considered
- **Rheumatoid Arthritis:** 400 mg initially and at Week 2 and Week 4, followed by 200 mg once every other week. For maintenance dosing, 400 mg once every 4 weeks may be considered.

#### **Availability**

Cimzia is available in cartons containing two **single-dose vials** along with other materials needed for administration, including sterile water diluent. Each vial contains 200 mg of certolizumab pegol lyophilized powder for reconstitution for SC administration. Contents of the carton should not be separated prior to use. Cimzia is also supplied in cartons of two **single-dose prefilled syringes**. Each prefilled syringe contains 200 mg of certolizumab pegol solution for SC administration. Additionally, the **prefilled syringes are available in a Starter Kit.** Each Start Kit contains six 200 mg prefilled syringes (three sets of two syringes each), to provide sufficient drug supply for the three initial induction doses at the start of treatment. Initial quantity limits provide a quantity sufficient for a 28-day supply of 400 mg every 4 weeks and one induction dose regimen per 365 days. Override criteria provide for additional quantities for patients receiving induction re-dosing or for patients requiring 400 mg every two weeks for the treatment of plaque psoriasis.

## **POLICY STATEMENT**

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Cimzia and to manage potential premature dose escalation. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration, unless otherwise noted below.

#### Automation: None.

# **Drug Quantity Limits**

Product	Strength and Form	Retail	Home Delivery
		Maximum Quantity	Maximum Quantity
Cimzia <sup>®</sup>	200 mg vials	2 vials per 28 days	6 vials per 84 days
(certolizumab pegol SC injection	(two vials per carton)		
[lyophilized powder or solution])	200 mg prefilled syringes	2 syringes per 28 days	6 syringes per 84 days
	(two syringes per carton)		
	200 mg prefilled syringes in a	6 syringes per 365 days	6 syringes per 365 days
	Starter Kit (6 syringes per kit)		

## **CRITERIA**

# Cimzia 200 mg prefilled syringes or vials

- 1. If the patient is requesting Cimzia for the treatment of plaque psoriasis, approve a quantity of 4 prefilled syringes or vials per 28 days at retail or 12 prefilled syringes or vials per 84 days at home delivery.
- 2. If the patient is initiating treatment with Cimzia or requires additional induction dosing, as verified by the absence of claims for Cimzia in the past 130 days, approve a one-time override for 6 prefilled syringes or vials at retail or 10 prefilled syringes or vials at home delivery.

# Cimzia 200 mg prefilled syringe Starter Kit

If the patient requires additional induction dosing, as verified by the absence of claims for Cimzia in the past 130 days, approve a one-time override for one starter pack (6 prefilled syringes) at retail or home delivery.

Inflammatory Conditions –	Cimzia D	OQM Policy -	Per Days
Page 3			

# REFERENCES

1. Cimzia® subcutaneous injection [prescribing information]. Smyrna, GA: UCB; September 2019.